Wound Therapy Firm Pushes For More Flexibility In Coverage-With-Evidence Conditions
This article was originally published in The Gray Sheet
Executive Summary
CMS recently proposed to lift a long-established non-coverage policy for platelet-rich plasma wound therapy, but only for patients enrolled in a randomized trial. Manufacturer Cytomedix says a registry-based observational study would be a better approach.
You may also be interested in...
CMS In Brief
Medicare advisors to meet on ventricular assist devices. CMS decides on coverage-with-evidence development for platelet-rich plasma wound care gel. More news from the Medicare agency.
News In Brief
Smith & Nephew launches orthobiologics spinout. CMS proposes CED for wound care gel. More news briefs.
Cytomedix Says Wound-Healing 510(k) Will Help Its Case With Medicare
Cytomedix's hard-won FDA clearance of its wound-healing device will lend strength to the company's pursuit of national Medicare coverage, the firm says